
## Ã%ika Cristina Pavarino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10456190/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Differential microRNA expression profile in blood of children with Down syndrome suggests a role in immunological dysfunction. Human Cell, 2022, 35, 639-648.	2.7	2
2	Regulation of VEGFA, KRAS, and NFE2L2 Oncogenes by MicroRNAs in Head and Neck Cancer. International Journal of Molecular Sciences, 2022, 23, 7483.	4.1	5
3	Polymorphisms in xenobiotic metabolism-related genes in patients with hepatocellular carcinoma: a case–control study. Xenobiotica, 2021, 51, 1-9.	1.1	5
4	Evaluation of molecular markers GSTM1 and GSTT1 and clinical factors in breast cancer: case-control study and literature review. Xenobiotica, 2021, 51, 1326-1334.	1.1	4
5	One-carbon metabolism and global DNA methylation in mothers of individuals with Down syndrome. Human Cell, 2021, 34, 1671-1681.	2.7	3
6	Association between folate metabolism polymorphisms and breast cancer: a case-control study. Genetics and Molecular Biology, 2021, 44, e20200485.	1.3	4
7	MicroRNAs as regulators of VEGFA and NFE2L2 in cancer. Gene, 2020, 759, 144994.	2.2	21
8	Glutathione S-transferase Polymorphisms in Head and Neck Squamous Cell Carcinoma Treated with Chemotherapy and/or Radiotherapy. Asian Pacific Journal of Cancer Prevention, 2020, 21, 1637-1644.	1.2	5
9	Gene Polymorphisms Involved in Folate Metabolism and DNA Methylation with the Risk of Head and Neck Cancer. Asian Pacific Journal of Cancer Prevention, 2020, 21, 3751-3759.	1.2	8
10	Molecular evaluation of glutathione S transferase family genes in patients with sporadic colorectal cancer. World Journal of Gastroenterology, 2018, 24, 4462-4471.	3.3	12
11	Interleukin 6 and 10 Serum Levels and Genetic Polymorphisms in Children with Down Syndrome. Mediators of Inflammation, 2018, 2018, 1-9.	3.0	5
12	Relationship between CD44/CD133/CD117 cancer stem cells phenotype and Cetuximab and Paclitaxel treatment response in head and neck cancer cell lines. American Journal of Cancer Research, 2018, 8, 1633-1641.	1.4	10
13	Clinical, Epidemiological and Histopathological Aspects in Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation. Asian Pacific Journal of Cancer Prevention, 2018, 19, 2795-2802.	1.2	5
14	Hepatocellular Carcinoma: a Comprehensive Review of Biomarkers, Clinical Aspects, and Therapy. Asian Pacific Journal of Cancer Prevention, 2017, 18, 863-872.	1.2	62
15	Differential Expression of Inflammation-Related Genes in Children with Down Syndrome. Mediators of Inflammation, 2016, 2016, 1-8.	3.0	12
16	<i>CYP1A1</i> , <i>CYP2E1</i> and <i>EPHX1</i> polymorphisms in sporadic colorectal neoplasms. World Journal of Gastroenterology, 2016, 22, 9974.	3.3	16
17	Polymorphisms of folate metabolism genes in patients with cirrhosis and hepatocellular carcinoma. World Journal of Hepatology, 2016, 8, 1234.	2.0	18
18	Neurofibromatosis: part 2 – clinical management. Arquivos De Neuro-Psiquiatria, 2015, 73, 531-543.	0.8	10

#	Article	IF	CITATIONS
19	Neurofibromatoses: part 1 ? diagnosis and differential diagnosis. Arquivos De Neuro-Psiquiatria, 2014, 72, 241-250.	0.8	27
20	Genetic Polymorphisms Involved in Folate Metabolism and Maternal Risk for Down Syndrome: A Meta-Analysis. Disease Markers, 2014, 2014, 1-12.	1.3	18
21	DNMT3B C46359T and SHMT1 C1420T polymorphisms in the folate pathway in carcinogenesis of head and neck. Molecular Biology Reports, 2014, 41, 581-589.	2.3	17
22	Altered Expression of Immune-Related Genes in Children with Down Syndrome. PLoS ONE, 2014, 9, e107218.	2.5	23
23	Association between GSTP1, GSTM1 and GSTT1 polymorphisms involved in xenobiotic metabolism and head and neck cancer development. Molecular Biology Reports, 2013, 40, 4181-4188.	2.3	10
24	<i>DHFR</i> 19-bp Deletion and <i>SHMT</i> C1420T Polymorphisms and Metabolite Concentrations of the Folate Pathway in Individuals with Down Syndrome. Genetic Testing and Molecular Biomarkers, 2013, 17, 274-277.	0.7	7
25	Head and neck cancer: causes, prevention and treatment. Brazilian Journal of Otorhinolaryngology, 2013, 79, 239-247.	1.0	105
26	<i>BHMT</i> G742A and <i>MTHFD1</i> G1958A Polymorphisms and Down Syndrome Risk in the Brazilian Population. Genetic Testing and Molecular Biomarkers, 2012, 16, 628-631.	0.7	14
27	Association between 11 genetic polymorphisms in folate-metabolising genes and head and neck cancer risk. European Journal of Cancer, 2012, 48, 1525-1531.	2.8	27
28	Clinical and epidemiological characteristics of patients in the head and neck surgery department of a university hospital. Sao Paulo Medical Journal, 2012, 130, 307-313.	0.9	22
29	Polymorphisms and haplotypes in methylenetetrahydrofolate reductase gene and head and neck squamous cell carcinoma risk. Molecular Biology Reports, 2012, 39, 635-643.	2.3	20
30	Polymorphisms of the CYP1A1 and CYP2E1 genes in head and neck squamous cell carcinoma risk. Molecular Biology Reports, 2012, 39, 1055-1063.	2.3	19
31	Polymorphism C1420T of Serine hydroxymethyltransferase gene on maternal risk for Down syndrome. Molecular Biology Reports, 2012, 39, 2561-2566.	2.3	16
32	Maternal risk for Down syndrome is modulated by genes involved in folate metabolism. Disease Markers, 2012, 32, 73-81.	1.3	27